Full Chapter Cancer Oxidative Stress and Dietary Antioxidants 2Nd Edition Vinood B Patel PDF
Full Chapter Cancer Oxidative Stress and Dietary Antioxidants 2Nd Edition Vinood B Patel PDF
Full Chapter Cancer Oxidative Stress and Dietary Antioxidants 2Nd Edition Vinood B Patel PDF
https://textbookfull.com/product/toxicology-oxidative-stress-and-
dietary-antioxidants-1st-edition-vinood-b-patel/
https://textbookfull.com/product/aging-oxidative-stress-and-
dietary-antioxidants-2nd-edition-victor-r-preedy/
https://textbookfull.com/product/aging-oxidative-stress-and-
dietary-antioxidants-victor-r-preedy/
https://textbookfull.com/product/molecular-nutrition-
vitamins-1st-edition-vinood-b-patel/
L Arginine in Clinical Nutrition 1st Edition Vinood B.
Patel
https://textbookfull.com/product/l-arginine-in-clinical-
nutrition-1st-edition-vinood-b-patel/
https://textbookfull.com/product/oxidative-stress-eustress-and-
distress-1st-edition-helmut-sies-editor/
https://textbookfull.com/product/measuring-oxidants-and-
oxidative-stress-in-biological-systems-lawrence-j-berliner/
https://textbookfull.com/product/oxidative-stress-and-redox-
signalling-in-parkinson-s-disease-1st-edition-rodrigo-franco/
https://textbookfull.com/product/early-phase-cancer-
immunotherapy-1st-edition-sandip-pravin-patel/
Cancer
Oxidative Stress and Dietary Antioxidants
This page intentionally left blank
Cancer
Oxidative Stress and Dietary Antioxidants
Second Edition
Edited by
Victor R. Preedy
Department of Nutrition and Dietetics, King’s College London, London, United Kingdom
Department of Clinical Biochemistry, King’s College Hospital, London, United Kingdom
Vinood B. Patel
University of Westminster, London, United Kingdom
Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
© 2021 Elsevier Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or
mechanical, including photocopying, recording, or any information storage and retrieval system, without
permission in writing from the publisher. Details on how to seek permission, further information about the
Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance
Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the Publisher
(other than as may be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden
our understanding, changes in research methods, professional practices, or medical treatment may
become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in evaluating
and using any information, methods, compounds, or experiments described herein. In using such
information or methods they should be mindful of their own safety and the safety of others, including
parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume
any liability for any injury and/or damage to persons or property as a matter of products liability,
negligence or otherwise, or from any use or operation of any methods, products, instructions,
or ideas contained in the material herein.
Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
ISBN: 978-0-12-819547-5
The book Cancer: Oxidative Stress and Dietary Antioxidants, Second Edition bridges the transdisciplinary divide and
covers the science of oxidative stress in cancer and the therapeutic use of antioxidants in food matrix in a single volume.
The second edition covers new investigations used to determine the comprehensive properties of antioxidants, food
items, and extracts, as well as any adverse properties they may have. It has been updated to include new clinical human
trials and studies dedicated to models of cancer. Furthermore, studies showing the beneficial effects of plant or natural
extracts provide the foundation for further rigorous studies in clinical trials. Throughout the book the processes within
the science of oxidative stress are described in concert with other processes, such as apoptosis, cell signaling, and
receptor-mediated responses. This approach recognizes that diseases are often multifactorial, and oxidative stress is a single
component of this.
The book Cancer: Oxidative Stress and Dietary Antioxidants, Second Edition contains two sections. Section A
covers oxidative stress and cancer in breast, prostate, lung, stomach, bladder, ovarian, cervical, and colorectal. In
Section B the focus is on antioxidants covering vitamins such as folic acid, vitamin C, vegetarian diets, fruit juices; caffeine
analogues, omega-3 fatty acids, Manuka honey; natural antioxidants such as lycopene, cinnamon, selenium, zinc, as well as
plant-derived products including anthocyanins, polyphenols, ginger root, Lycium barbarum, and fern extracts, where
models of cancer are also discussed.
Each chapter has Summary Points and a section on Applications to Other Areas of Cancer. Finally we conclude with a
chapter on resources and further reading, coverage includes:
Key books and further reading
Key societies
Key research organizations
Analytical platforms
Governmental bodies
Journals covering cancer and oxidative stress
Thus, this text is relevant to biologists, biochemists, nutritionists, dieticians, and nutrition researchers as cancer is a
multifaceted process covering disease processes, clinical research, and treatment.
v
This page intentionally left blank
Contents
vii
viii Contents
CA hampers glucose uptake and glucose Apple and oxidative balance 295
catabolism to lactate in cervical Apple and cancer 295
cancer cells 282 Grape and wine 295
CA induces oxidative stress in mitochondria Grape/wine and cancer 296
and elucidates metabolic-dependent Summary points 297
apoptotic death in epithelial cervical References 297
cancer cells 283
CA impairs energy generation in cervical 27. Oxidative stress and cancer:
cancer cells 284 Antioxidative role of Ayurvedic
Energetic stress caused by CA in cervical plants
cancer cells activates adenosine
50 -monophosphate AMP-activated Sahdeo Prasad and Sanjay K. Srivastava
protein kinase 284 Introduction 301
CA affects the cervical cancer cells Oxidative stress and cancer 302
phenotype and migration properties Ayurvedic plants with antioxidative
under implementation of the Epithelial- nature 302
to-Mesenchymal Transition process 285 Emblica officinalis 302
CA has the potency to regulate cell cycle Glycyrrhiza glabra 303
progress in cervical cancer cells with an Aloe vera 304
epithelial phenotype 286 Ocimum sanctum 304
Applications to other conditions 287 Tinospora cordifolia 305
Cervical cancer treatment in humans using Other Ayurvedic plants 305
Cisplatin 287 Conclusion 307
Co-treatment of cervical cancer cells with Summary points 307
CA and the antidiabetic drug, Metformin, Acknowledgments 307
augments the toxic action of Cisplatin via Conflict of interest 307
regulation of the cell cycle—In vitro References 308
study 287
CA and Met hamper proliferation and 28. Polyphenol chlorogenic acid,
enhance cell death in cervical cancer
antioxidant profile, and breast
cells but not in normal cells 287
CA alleviates lactic acidosis caused by
cancer
Metformin—In vitro study 288 Onur Bender and Arzu Atalay
Bioavailability of CA and perspectives of
Introduction 312
use in humans 288
Chlorogenic acid 312
Summary points 288
Antioxidant profile of chlorogenic acid 313
References 288
Antioxidant capacity of chlorogenic
acid isomers with conventional in
26. Effects of caffeic acid on oxidative vitro tests 313
balance and cancer Antioxidant properties of chlorogenic acid
Beatriz da Silva Rosa Bonadiman, in cellular level 313
Grazielle Castagna Cezimbra Weis, Antioxidant effects of chlorogenic acid
J
essica Righi da Rosa, Charles Elias Assmann, in vivo 314
Audrei de Oliveira Alves, P^
amela Longhi, and Computational evaluations for antioxidant
Margarete Dulce Bagatini
potential of chlorogenic acid 316
Coffee 291 Chlorogenic acid and breast cancer 316
Coffee and oxidative balance 291 Cytotoxic/antiproliferative effects of
Coffee and cancer 291 chlorogenic acid on breast cancer cells 316
Berries 292 Effects of chlorogenic acid on cell cycle
Raspberry 292 distribution in breast cancer 318
Blueberry 293 Apoptotic effects of chlorogenic acid on
Propolis 294 breast cancer 318
Propolis and oxidative balance 294 Effects of chlorogenic acid on
Propolis and cancer 294 mitochondrial membrane potential in
Apple 295 breast cancer 319
xiv Contents
Curcumin and a multifunctional nuclear Infrared radiation (IR) and visible light (VIS)
transcription factor and the enzyme and oxidative stress 388
manganese superoxide dismutase protein Fernblock, oxidative stress, and
expression 362 photoprotection 389
Curcumin and lipid peroxidation 364 Photoprotective agents 389
Curcumin and epithelial-mesenchymal Polypodium leucotomos. Origen and
transition 364 composition 389
Curcumin and genomic instability 365 Composition 389
Curcumin and specific biomarkers for Molecular, cellular, and clinical evidence of
cancer 366 the photoprotective properties of
Summary points 368 Fernblock 389
Acknowledgments 368 Fernblock in DNA photodamage and
References 369 repair 389
Fernblock effect on free radicals during
33. Curcumin analogs, oxidative stress, inflammation 390
and prostate cancer Fernblock prevents UV radiation-mediated
immunosuppression 391
Marco Bisoffi and Justin M. O’Neill Fernblock, an anti-UV-induced tumor
Introduction 372 progression agent 391
Prostate cancer and oxidative stress 372 Fernblock and malignant melanoma 393
Prostate cancer: A brief introduction 372 Fernblock prevention of matrix remodeling
Prostate cancer and oxidative stress: and other cellular effects 393
Possible factors 373 Fernblock preventions of photodamage
Reactive oxygen species: A paradox in induced by visible light and infrared
(prostate) cancer 373 radiation 394
Curcumin, curcuminoids, and curcumin Potential use of Fernblock in the
analogs 374 treatment of other pathological skin
Chemistry and biochemistry of curcumin, conditions 395
curcuminoids, and curcumin analogs 374 Idiopathic photodermatosis 395
Antioxidant versus prooxidant activities of Pigmentary disorders 395
curcumin, curcuminoids, and curcumin Applications to Fernblock to skin cancers
analogs 376 or other conditions 396
The potential of curcumin, curcuminoids, Summary points 396
and curcumin analogs as oxidant agents in Acknowledgments 396
prostate cancer 380 References 396
Molecular targets of curcumin,
curcuminoids, and curcumin analogs in
prostate cancer 380 35. Lycium barbarum (goji berry),
Curcumin, curcuminoids, and curcumin human breast cancer, and
analogs as antioxidants in prostate antioxidant profile
cancer 380
Anna Wawruszak, Marta Halasa,
Curcumin, curcuminoids, and curcumin and Karolina Okla
analogs as prooxidants in prostate
cancer 381 Introduction 399
Summary points 384 Natural compounds in cancer therapy
References 384 and chemoprevention 400
Characteristics of Lycium barbarum
34. Fern extract, oxidative stress, and (goji berry) 400
skin cancer Anticancer properties of L. barbarum in
breast cancer 401
Concepción Parrado, Yolanda Gilaberte, Antioxidative properties of L. barbarum
Neena Philips, Angeles Juarranz, and in breast cancer 402
Salvador Gonzalez
Applications to other cancers or
Introduction 388 conditions 403
Ultraviolet radiation and Summary points 404
oxidative stress 388 References 404
xvi Contents
Numbers in parenthesis indicate the pages on which the authors’ Arzu Atalay (311), Biotechnology Institute, Ankara Uni-
contributions begin. versity, Ankara, Turkey
Behnaz Abiri (539), Department of Nutrition, Faculty of Luigi Avallone (505), Department of Veterinary Medicine
Paramedicine, Ahvaz Jundishapur University of and Animal Production, University of Naples Federico
Medical Sciences, Ahvaz, Iran II, Naples, Italy
Sadia Afrin (407), Department of Gynecology and Khaled Aziz (131), Medical Scientist Training Program,
Obstetrics, Johns Hopkins University, School of Med- Mayo Graduate School, Mayo Clinic, College of Med-
icine, Baltimore, MD, United States icine, Rochester, MN, United States
Yolanda Aguilera (265), Institute of Food Science Margarete Dulce Bagatini (291), Academic Coordination,
Research, CIAL (UAM-CSIC), Department of Agricul- Campus Chapecó, Federal University of Fronteira Sul,
tural Chemistry and Food Science, Universidad Chapecó, SC, Brazil
Autónoma de Madrid, Madrid, Spain Giuseppina Barrera (159), Department of Clinical and
Mazhar Al Zoubi (101), Department of Basic Medical Sci- Biological Sciences, University of Turin, Torino, Italy
ences, Faculty of Medicine, Yarmouk University, Irbid, Saime Batırel (465), Faculty of Medicine, Department of
Jordan Medical Biochemistry, Marmara University, Istanbul,
Alaa Aljabali (101), Department of Pharmaceutical Sci- Turkey
ences, Faculty of Pharmacy, Yarmouk University, Irbid, Maurizio Battino (407), Department of Analytical and
Jordan Food Chemistry, Nutrition and Food Science Group,
Anmar Al-Taie (179), Head of Clinical Pharmacy CITACA, CACTI, University of Vigo, Vigo Campus,
Department, Faculty of Pharmacy, Girne American Uni- Vigo, Spain; Department of Clinical Sciences, Uni-
versity, Kyrenia, Turkey versità Politecnica delle Marche, Ancona, Italy; Interna-
Tsukuru Amano (77), Department of Obstetrics & Gyne- tional Research Center for Food Nutrition and Safety,
cology, Shiga University of Medical Science, Ostu, Japan Jiangsu University, Zhenjiang, China
Pilar Amiano (219), Ministry of Health of the Basque Gov- Onur Bender (311), Biotechnology Institute, Ankara Uni-
ernment, Public Health Division of Gipuzkoa, Biodo- versity, Ankara, Turkey
nostia Health Research Institute, Donostia-San Daniel Pereira Bezerra (417), Gonçalo Moniz Institute,
Sebastian; CIBERESP (Consortium for Biomedical Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Sal-
Research in Epidemiology and Public Health), Madrid, vador, Bahia, Brazil
Spain Ranjana Bhandari (203), Pharmacology Research Labo-
Ayca Ant (55), Department of Otorhinolaryngology, Head ratory, University Institute of Pharmaceutical Sciences,
and Neck Surgery, University of Health Sciences UGC-Centre of Advanced Study, Panjab University,
Ankara A.Y. Oncology Education and Research Hos- Chandigarh, India
pital, Yenimahalle/Ankara, Turkey Marco Bisoffi (371), Chemistry and Biochemistry, Schmid
Mahboobeh Ashrafi (255), Division of Biochemistry, College of Science and Technology, Chapman Uni-
Department of Basic Sciences, School of Veterinary versity, Orange, CA, United States
Medicine, Shiraz University, Shiraz, Iran Bianka Bojková (111), Department of Animal Physiology,
Charles Elias Assmann (291), Department of Biochem- Institute of Biology and Ecology, Faculty of Science,
istry and Molecular Biology, PPGBTox, CCNE, Federal Pavol Jozef Šafárik University in Košice, Košice,
University of Santa Maria, Santa Maria, RS, Brazil Slovak Republic
xix
xx Contributors
Chanchai Boonla (67), Department of Biochemistry, Marie Angele Cucci (159), Department of Clinical and
Faculty of Medicine, Chulalongkorn University, Biological Sciences, University of Turin, Torino, Italy
Bangkok, Thailand Joseph J. Cullen (515), Free Radical and Radiation
Garry R. Buettner (515), Free Radical and Radiation Biology Program, Departments of Surgery and Radi-
Biology Program, Departments of Surgery and Radi- ation Oncology, Holden Comprehensive Cancer Center,
ation Oncology, Holden Comprehensive Cancer Center, The University of Iowa Hospitals and Clinics, The Uni-
The University of Iowa Hospitals and Clinics, The Uni- versity of Iowa College of Medicine, and the Iowa City
versity of Iowa College of Medicine, and the Iowa City Veterans Affairs, Iowa City, IA, United States
Veterans Affairs, Iowa City, IA, United States Jessica Righi da Rosa (291), Department of Technology
David Bynum (439), School of Natural Sciences, Uni- and Food Science, Rural Science Center, Federal Uni-
versity College, Fairleigh Dickinson University, versity of Santa Maria, Santa Maria, RS, Brazil
Teaneck, NJ, United States Beatriz da Silva Rosa Bonadiman (291), Department of
Viola Calabrò (505), Department of Biology, Complesso Biological Science: Biochemistry, Federal University
Universitario Monte S. Angelo, University of Naples of Santa Catarina, Florianópolis, SC, Brazil
Federico II, Naples, Italy Sreemanti Das (191), Cytogenetics and Molecular Biology
Gloria M. Calaf (359), Instituto de Alta Investigación, Laboratory, Department of Zoology, University of
Universidad de Tarapaca, Arica, Chile; Columbia Uni- Kalyani, Kalyani, India
versity Medical Center, New York, NY, United States Christophe Deben (39), Center for Oncological Research,
Domenico Carotenuto (505), UNMSM, Universidad University of Antwerp, Wilrijk, Belgium
Nacional Mayor San Marcos, Lima, Peru Andrea Devecchi (245), Department of Clinical Nutrition,
Rory S. Carroll (515), Free Radical and Radiation AOU Città della Salute e della Scienza, Turin, Italy
Biology Program, Departments of Surgery and Radi- Valentina D’Onofrio (245), Department of Clinical
ation Oncology, Holden Comprehensive Cancer Nutrition, AOU Città della Salute e della Scienza, Turin,
Center, The University of Iowa Hospitals and Clinics, Italy
The University of Iowa College of Medicine, and the
Iowa City Veterans Affairs, Iowa City, IA, United Sepideh Elyasi (483), Department of Clinical Pharmacy,
States Faculty of Pharmacy, Mashhad University of Medical
Sciences, Mashhad, Iran
Tokuhiro Chano (77), Department of Clinical Laboratory
Medicine and Medical Genetics, Shiga University of Fatma Ceyla Eraldemir (3), Department of Biochemistry,
Medical Science, Ostu, Japan Faculty of Medicine, Kocaeli University, Kocaeli,
Turkey
Matthew Cheesman (495), School of Pharmacy and Phar-
macology, Griffith University; Menzies Health Institute Luigi Esposito (505), Department of Veterinary Medicine
Queensland, Quality Use of Medicines Network, and Animal Production, University of Naples Federico
Southport, QLD, Australia II, Naples, Italy
Rong-Jane Chen (451), Department of Food Safety/ Maurizio Fadda (245), Department of Clinical Nutrition,
Hygiene and Risk Management, College of Medicine, AOU Città della Salute e della Scienza, Turin, Italy
National Cheng Kung University, Tainan, Taiwan Bianca Cristine Favero-Santos (121), Obesity and
Francesca Ciani (505), Department of Veterinary Med- Comorbidities Research Centre, Department of Struc-
icine and Animal Production, University of Naples Fed- tural and Functional Biology, Institute of Biology, Uni-
erico II, Naples, Italy versity of Campinas, Campinas, SP, Brazil
Natascia Cocchia (505), Department of Veterinary Med- Ana S. Fernandes (235), CBIOS, Research Center for Bio-
icine and Animal Production, University of Naples Fed- sciences & Health Technologies – School of Health Sci-
erico II, Naples, Italy ences and Technologies, Lusófona University, Lisbon,
Portugal
Ian Edwin Cock (495), School of Environment and
Science; Environmental Futures Research Institute, Cı́ntia Ferreira-P^ego (235), CBIOS, Research Center for
Griffith University, Nathan, QLD, Australia Biosciences & Health Technologies – School of Health
Sciences and Technologies, Lusófona University,
João G. Costa (235), CBIOS, Research Center for Biosci- Lisbon, Portugal
ences & Health Technologies – School of Health Sci-
ences and Technologies, Lusófona University, Lisbon, Concetta Finocchiaro (245), Department of Clinical
Portugal Nutrition, AOU Città della Salute e della Scienza, Turin,
Italy
Contributors xxi
Cesira Foppoli (87), CNR Institute of Molecular Biology Zuhair Mohammad Hassan (475), Department of Immu-
and Pathology, Sapienza University of Rome, Rome, nology, School of Medical Sciences, Tarbiat Modares
Italy University, Tehran, Iran
Tamara Y. Forbes-Hernández (407), Department of Ana- Vasiliki I. Hatzi (131), Laboratory of Health Physics &
lytical and Food Chemistry, Nutrition and Food Science Environmental Health, Institute of Nuclear Technology
Group, CITACA, CACTI, University of Vigo, Vigo & Radiation Protection, National Center for Scientific
Campus, Vigo, Spain Research “Demokritos”, Athens, Greece
Laurie Freire Boullosa (39), Center for Oncological Cristan A. Herbert (27), Mechanisms of Disease and
Research, University of Antwerp, Wilrijk, Belgium Translational Research, School of Medical Sciences,
Jessica Gambardella (171), Department of Advanced Bio- Faculty of Medicine, UNSW Sydney, Sydney, NSW,
medical Sciences, Federico II University, Napoli, Italy Australia
Belen Garcı́a-Villanova (219), Department of Nutrition Guido Iaccarino (171), Department of Advanced Bio-
and Bromatology, Faculty of Pharmacy, University of medical Sciences, Federico II University, Napoli, Italy
Granada, Granada, Spain Mirko Ippolito (245), Department of Clinical Nutrition,
Alexandros G. Georgakilas (131), DNA Damage Labo- AOU Città della Salute e della Scienza, Turin, Italy
ratory, Physics Department, School of Applied Mathe- Fikret Vehbi Izzettin (179), Head of Clinical Pharmacy
matics and Physical Sciences, National Technical Department, Faculty of Pharmacy, Bezmialem Vakif
University of Athens (NTUA), Athens, Greece University, Istanbul, Turkey
Francesca Giampieri (407), Department of Analytical and Angeles Juarranz (387), Biology Department, Sciences
Food Chemistry, Nutrition and Food Science Group, School, Universidad Autónoma de Madrid, Madrid,
CITACA, CACTI, University of Vigo, Vigo Campus, Spain
Vigo, Spain; Department of Clinical Sciences, Uni- Daehee Kang (523), Department of Preventive Medicine,
versità Politecnica delle Marche, Ancona, Italy; College Seoul National University College of Medicine, Seoul,
of Food Science and Technology, Northwest University, Republic of Korea
Xi’an, Shaanxi, China
Rui Kang (149), Department of Surgery, UT Southwestern
Yolanda Gilaberte (387), Dermatology Service, Miguel Medical Center, Dallas, TX, United States
Servet Hospital, Zaragoza, Spain
Garima Khanna (203), Pharmacology Research Labo-
Maria Cristina Cintra Gomes-Marcondes (121), Labo- ratory, University Institute of Pharmaceutical Sciences,
ratory of Nutrition and Cancer, Department of Structural UGC-Centre of Advanced Study, Panjab University,
and Functional Biology, Institute of Biology, University Chandigarh, India
of Campinas, Campinas, SP, Brazil
Anisur Rahman Khuda-Bukhsh (191), Emeritus of Uni-
Salvador Gonzalez (387, 439), Dermatology Service, versity Grants Commission at University of Kalyani,
Memorial Sloan-Kettering Cancer Center, New York, Kalyani, India
NY, United States; Medicine and Medical Specialties
Department, Alcala University, Madrid, Spain Tuğcan Korak (3), Department of Medical Biology,
Faculty of Medicine, Kocaeli University, Kocaeli,
Elvira Gonzalez de Mejia (265), Department of Food Turkey
Science and Human Nutrition, Division of Nutritional
Sciences, University of Illinois at Urbana-Champaign, Anurag Kuhad (203), Pharmacology Research Labo-
Champaign, IL, United States ratory, University Institute of Pharmaceutical Sciences,
UGC-Centre of Advanced Study, Panjab University,
Luis Goya (337), Department of Metabolism and Nutrition, Chandigarh, India
Institute of Food Science, Technology and Nutrition
(ICTAN-CSIC), Ciudad Universitaria, Madrid, Spain Natalia Kurhaluk (111), Department of Zoology and
Animal Physiology, Institute of Biology and Earth Sci-
Margherita Grattarola (159), Department of Clinical and ences, Pomeranian University, Slupsk, Poland
Biological Sciences, University of Turin, Torino, Italy
Byoung-Mog Kwon (323), Laboratory of Chemical
Eduardo Jesús Guerra-Hernández (219), Department of Biology and Genomics, Korea Research Institute of
Nutrition and Bromatology, Faculty of Pharmacy, Uni- Bioscience and Biotechnology, Daejeon, Republic of
versity of Granada, Granada, Spain Korea
Marta Halasa (399), Department of Biochemistry and Sang-Ah Lee (523), Department of Preventive Medicine,
Molecular Biology, Medical University of Lublin, Kangwon National University School of Medicine,
Lublin, Poland Chuncheon-si, Gangwon-do, Republic of Korea
xxii Contributors
Jinthe Van Loenhout (39), Center for Oncological Justin M. O’Neill (371), Chemistry and Biochemistry,
Research, University of Antwerp, Wilrijk, Belgium Schmid College of Science and Technology, Chapman
Wei Sheng Joshua Loke (27), Department of Respiratory University, Orange, CA, United States
Medicine, Prince of Wales Hospital, Randwick; Jane O’Sullivan (427), Department of Anaesthesiology
Prince of Wales’ Clinical School and Mechanisms of and Critical Care, Tallaght University Hospital, Dublin,
Disease and Translational Research, Faculty of Med- Ireland
icine, University of New South Wales, Sydney, NSW, Karolina Okla (399), The First Department of Gyneco-
Australia logical Oncology and Gynecology, Medical University
P^
amela Longhi (291), Department Life Science and of Lublin, Lublin, Poland
Health, University of the West of Santa Catarina, Melina de Moraes Santos Oliveira (121), Laboratory of
Xanxer^e, SC, Brazil Nutrition and Cancer, Department of Structural and
Olga A. Martin (131), Sir Peter MacCallum Department of Functional Biology, Institute of Biology, University of
Oncology, The University of Melbourne, Melbourne, Campinas, Campinas, SP, Brazil
VIC, Australia Nuno G. Oliveira (235), Research Institute for Medicines
Maria Angeles Martı́n (337), Department of Metabolism (iMed.ULisboa), Faculty of Pharmacy, Universidade de
and Nutrition, Institute of Food Science, Technology Lisboa, Lisbon, Portugal
and Nutrition (ICTAN-CSIC), Ciudad Universitaria, Sarah Christine Pereira de Oliveira (121), Laboratory of
Madrid, Spain Nutrition and Cancer, Department of Structural and
Maria A. Martı́n-Cabrejas (265), Institute of Food Functional Biology, Institute of Biology, University of
Science Research, CIAL (UAM-CSIC), Department of Campinas, Campinas, SP, Brazil
Agricultural Chemistry and Food Science, Universidad Audrei de Oliveira Alves (291), Department of Physiology
Autónoma de Madrid, Madrid, Spain and Pharmacology, Federal University of Santa Maria,
Lucianna Maruccio (505), Department of Veterinary Santa Maria, RS, Brazil
Medicine and Animal Production, University of Naples Concepción Parrado (387), Department of Histology and
Federico II, Naples, Italy Pathology, Faculty of Medicine, University of Málaga,
Emmanuel Mfotie Njoya (349), Institute of Pharmacy, Málaga, Spain
Martin-Luther University of Halle-Wittenberg, Halle Vinood B. Patel (547), University of Westminster, School
(Saale), Germany; Department of Biochemistry, Faculty of Life Sciences, London, United Kingdom
of Science, University of Yaounde I, Yaounde, Cameroon
Marzia Perluigi (87), Department of Biochemical Sci-
Natalia Angelo da Silva Miyaguti (121), Laboratory of ences, Sapienza University of Rome, Rome, Italy
Nutrition and Cancer, Department of Structural and
Functional Biology, Institute of Biology, University of Rumana Pervin (427), Biochemistry & Molecular
Campinas, Campinas, SP, Brazil Biology, University of Rajshahi, Rajshahi, Bangladesh
Mahdieh Molanouri Shamsi (475), Physical Education & Neena Philips (387, 439), School of Natural Sciences, Uni-
Sport Sciences Department, Faculty of Humanities, versity College, Fairleigh Dickinson University,
Tarbiat Modares University, Tehran, Iran Teaneck, NJ, United States
Esther Molina-Montes (219), Genetic and Molecular Epi- Costanza Pira (245), Department of Clinical Nutrition,
demiology Group, Spanish National Cancer Research AOU Città della Salute e della Scienza, Turin, Italy
Center (CNIO), Madrid; Department of Nutrition and Stefania Pizzimenti (159), Department of Clinical and
Bromatology, Faculty of Pharmacy, University of Biological Sciences, University of Turin, Torino, Italy
Granada, Granada, Spain Md. Moyen Uddin Pk (427), Institute of Biological
Amir Mousapasandi (27), Prince of Wales’ Clinical Science, University of Rajshahi, Rajshahi; Biochem-
School and Mechanisms of Disease and Translational istry, Primeasia University; Independent University of
Research, School of Medical Sciences, Faculty of Med- Bangladesh; Clinical Biochemistry (Diagnostic), Anwer
icine, UNSW Sydney; Department of Respiratory Med- Khan Modern Medical College & Hospital, Dhaka; Bio-
icine, Prince of Wales Hospital, Randwick, Sydney, chemistry & Molecular Biology, University of Rajshahi,
NSW, Australia Rajshahi, Bangladesh
Somaira Nowsheen (131), Medical Scientist Training Alessandra Pollice (505), Department of Biology, Com-
Program, Mayo Graduate School, Mayo Clinic, College plesso Universitario Monte S. Angelo, University of
of Medicine, Rochester, MN, United States Naples Federico II, Naples, Italy
Contributors xxiii
Sahdeo Prasad (301), Department of Immunotherapeutics Tahoora Shomali (255), Division of Pharmacology and
and Biotechnology and Center for Tumor Immunology Toxicology, Department of Basic Sciences, School of
and Targeted Cancer Therapy, Texas Tech University Veterinary Medicine, Shiraz University, Shiraz, Iran
Health Sciences Center, Abilene, TX, United States Halyna Siomyk (439), School of Natural Sciences, Uni-
Victor R. Preedy (547), Diabetes and Nutritional Sciences versity College, Fairleigh Dickinson University,
Research Division, Faculty of Life Science and Med- Teaneck, NJ, United States
icine, King’s College London, London, United Shankar Siva (131), Department of Radiation Oncology,
Kingdom Peter MacCallum Cancer Centre; Sir Peter MacCallum
Matiar Rahman (427), Biochemistry & Molecular Department of Oncology, The University of Melbourne,
Biology, University of Rajshahi, Rajshahi, Bangladesh Melbourne, VIC, Australia
Rajkumar Rajendram (547), College of Medicine, King Daniela Sorriento (171), Department of Advanced Bio-
Saud bin Abdulaziz University for Health Sciences; medical Sciences, Federico II University, Napoli, Italy
Department of Medicine, King Abdulaziz Medical Sanjay K. Srivastava (301), Department of Immunothera-
City, Ministry of National Guard Health Affairs, peutics and Biotechnology and Center for Tumor Immu-
Riyadh, Saudi Arabia; Diabetes and Nutritional Sci- nology and Targeted Cancer Therapy, Texas Tech
ences Research Division, Faculty of Life Science and University Health Sciences Center, Abilene, TX, United
Medicine, King’s College London, London, United States
Kingdom
Hidekazu Suzuki (49), Division of Gastroenterology and
Sonia Ramos (337), Department of Metabolism and Hepatology, Department of Internal Medicine, Tokai
Nutrition, Institute of Food Science, Technology and University School of Medicine, Isehara, Kanagawa,
Nutrition (ICTAN-CSIC), Ciudad Universitaria, Japan
Madrid, Spain
Simona Tafuri (505), Department of Veterinary Medicine
Miguel Rebollo-Hernanz (265), Institute of Food Science and Animal Production, University of Naples Federico
Research, CIAL (UAM-CSIC), Department of Agricul- II, Naples, Italy
tural Chemistry and Food Science, Universidad
Autónoma de Madrid, Madrid, Spain Daolin Tang (149), Department of Surgery, UT South-
western Medical Center, Dallas, TX, United States
Richard Richardson (439), School of Natural Sciences,
University College, Fairleigh Dickinson University, Paul S. Thomas (27), Department of Respiratory Medicine,
Teaneck, NJ, United States Prince of Wales Hospital, Randwick; Prince of Wales’
Clinical School and Mechanisms of Disease and Trans-
Santu Kumar Saha (191), Newcastle University Centre for lational Research, Faculty of Medicine, University of
Cancer, Translational and Clinical Research Unit, New- New South Wales, Sydney, NSW, Australia
castle University, Newcastle upon Tyne, United Kingdom
Ioanna Tremi (131), DNA Damage Laboratory, Physics
Sweta Sharma Saha (191), Newcastle University Centre Department, School of Applied Mathematics and
for Cancer, Translational and Clinical Research Unit, Physical Sciences, National Technical University of
Newcastle University, Newcastle upon Tyne, United Athens (NTUA), Athens, Greece
Kingdom
Hitoshi Tsugawa (49), Department of Biochemistry, Keio
Carla de Moraes Salgado (121), Laboratory of Nutrition University School of Medicine, Tokyo, Japan
and Cancer, Department of Structural and Functional
Biology, Institute of Biology, University of Campinas, Malgorzata Tyszka-Czochara (281), Jagiellonian Uni-
Campinas, SP, Brazil versity Medical College, Faculty of Pharmacy, Department
of Food Chemistry and Nutrition, Krakow, Poland
Mesut Sancar (179), Head of the Clinical Pharmacy
Department, Faculty of Pharmacy, Marmara University, Mohammadreza Vafa (539), Department of Nutrition,
Istanbul, Turkey School of Public Health; Pediatric Growth and Devel-
opment Research Center, Institute of Endocrinology
Woo-Kyoung Shin (523), Department of Preventive Med- and Metabolism, Iran University of Medical Sciences,
icine, Seoul National University College of Medicine, Tehran, Iran
Seoul, Republic of Korea
Jessica Ventura (131), Department of Obstetrics & Gynae-
Masaki Shiota (15), Department of Urology, Graduate cology, The University of Melbourne and Royal
School of Medical Sciences, Kyushu University, Women’s Hospital, Melbourne, VIC, Australia
Fukuoka, Japan
xxiv Contributors
Laı́s Rosa Viana (121), Laboratory of Nutrition and Cancer, Grazielle Castagna Cezimbra Weis (291), Department of
Department of Structural and Functional Biology, Technology and Food Science, Rural Science Center,
Institute of Biology, University of Campinas, Campinas, Federal University of Santa Maria, Santa Maria, RS,
SP, Brazil Brazil
Bojana B. Vidovic (235), Faculty of Pharmacy, University Pawel J. Winklewski (111), Department of Human
of Belgrade, Belgrade, Serbia Physiology, Medical University of Gdansk, Gdansk,
Ying-Jan Wang (451), Department of Environmental and Poland
Occupational Health, College of Medicine, National Yae Jin Yoon (323), Laboratory of Chemical Biology
Cheng Kung University, Tainan, Taiwan and Genomics, Korea Research Institute of Bioscience
Anna Wawruszak (399), Department of Biochemistry and and Biotechnology, Daejeon, Republic of Korea
Molecular Biology, Medical University of Lublin,
Lublin, Poland
Section A
List of abbreviations
OH hydroxyl radical
AhR aryl hydrocarbon receptor
AP-1 activator protein 1
ARNT Aryl hydrocarbon receptor nuclear translocator
BC Breast cancer
BRCA breast cancer susceptibility gene
CHOP CCAAT/enhancer-binding protein homologous protein
CoQ10 coenzyme Q10
CREB cAMP response element binding
cytC cytochrome C
E2 Estradiol
ER endoplasmic reticulum
ERK extracellular-regulated kinase
FXR Farnesol X receptor
GR glucocorticoid receptor
GRE glucocorticoid response element
H2O2 hydrogen peroxide
HDL high-density lipoprotein
IGF-1 insulin like growth factor-1
IL interleukin
IMM inner mitochondrial membrane
IRS-1 insulin Receptor Substrate-1
JAK janus kinase
JNK c-Jun N-terminal kinase
LDL low-density lipoprotein
MAPK mitogen-activated protein kinase
MICAL1 molecule interacting with CasL 1
NF-kB nuclear factor-kB
Nrf2 nuclear factor erythroid 2-related factor 2
O2 oxygen
O2 superoxide
OMM outer mitochondrial membrane
PDGFR-b platelet-derived growth factor receptors b
PI3K/Akt phosphatidylinositol-3-kinase
PKC protein kinase C
PKD protein kinase D
PON paraoxonase
PPAR peroxisome proliferator-activated receptor
PPRE PPAR response element
PTEN phosphatase and tensin homolog
Cancer. https://doi.org/10.1016/B978-0-12-819547-5.00001-8
© 2021 Elsevier Inc. All rights reserved. 3
4 SECTION A Oxidative stress and cancer
Introduction
Breast cancer (BC) is a frequently encountered and is a leading cause of death in women worldwide. Oxidative stress is one
of the precipitating factors in the development of BC and can be due to a variety of causes including genetic factors, envi-
ronmental factors, advanced age, and long-term exposure to estrogen.1–3 Reactive oxygen species (ROS) may occur at
pathological levels and/or insufficient antioxidants could disturb the normal balance between oxidants, which are essential
elements in many cellular functions, and antioxidants leading to oxidative stress. The end result of oxidative stress is the
overproduction of ROS, which are extremely reactive molecules that can damage and thus modify the function of mac-
romolecules, such as nucleic acids, proteins, lipids, and carbohydrates. Antioxidant systems are critical for the neutrali-
zation of ROS. Oxidative stress may lead to various pathological conditions and diseases including cancers.4 Oxidative
stress has been implicated in BC, and oxidative stress crucially affects cell proliferation and malignancy as the BC
develops.3 In this regard, paraoxonases (PONs) are essential with respect to their capacity to inhibit oxidative stress based
on their antioxidant properties.5 The paraoxonase (PON) gene family is composed of three genes PON1, PON2, and PON3,
which are localized on chromosome 7.2 All three PON enzymes are calcium-dependent hydrolases6 and are involved in
hydrolyzing a variety of substrates, such as organophosphorus, lactones, aryl esters, and estrogen esters. Although some
of the substrates are hydrolyzed by all PONs, specificity of each enzyme to substrates could be different.6, 7
Based on their antioxidative effects, all three enzymes warrant further investigation in terms of their effect on the devel-
opment and progress of BC. Some polymorphisms of PON1 were reported to contribute BC risk, through polymorphic
variation in PON1 activity.2 On the other hand, PON2 and PON3 decrease the formation of superoxide by reducing the
formation of intracellular ROS.8 Thus, higher concentrations of PON2 and PON3 in healthy breast cells are beneficial
for cellular homeostasis. However, the antiapoptotic effect of these two PONs, by decreasing ROS concentrations in
the cancerous cell, makes the treatment of BC more difficult. Therefore, an evaluation of the available data, in terms
of the relationship with ROS and possible PONs-dependent molecular mechanisms of cancers, especially in BC, is merited.
Mary Queen of Scots, and Bonnie Prince Charlie! How they live
with us yet, casting their spell over the centuries!
If there is one figure in the past that still acts powerfully upon the
tradition, literature, and imagination of Scotland,—in a word, upon
that which remains and is imperishable, after stone and brass are
but mouldering relics,—it is the figure and fortunes of Charles, the
Young Pretender to the throne of Great Britain. With him ended
Celtic Scotland, Scottish feudalism, and the age of Highland
romance.
About the “Young Chevalier”—the image on the Scottish mind is
that of the fair youth in the full splendor of manhood; not the
wretched dregs of the human form that many years afterwards was
cast out of memory like an abominable branch. It is of the bonnie
young fellow that such songs as “Wae’s me for Prince Charlie,”
“Charlie is my darling,” “Come o’er the stream, Charlie,” and “The
White Cockade,” were written and are still sung. His full name was
Charles Edward Louis Philippe Casimir Stuart.
This young man, of extraordinary beauty and fascinating
manners, against the advice of his friends and most loyal supporters,
landed in Scotland, and summoning the Highland chiefs, who, by
affinities of blood, politics, and religion, were most attached to the
Stuart dynasty, asked for their support. One and all, they declared
against the uprising, but they, nevertheless, agreed to follow their
liege lord.
Born at Rome, on December 31, 1720, grandson of King James
II of England, and eldest son of James, the Old Pretender, who
called himself James III, Charles was nominated by his family the
Prince of Wales. Educated under brilliant tutors, he travelled through
Italy. He was able to speak English, French, and Italian, but could
never write well in English. Despite the previous failure, in 1715, of
his father, and the loss at sea by storm of a French fleet, with seven
thousand men who were to assist his Highlanders, Charles landed in
Scotland when most of the British army was in the Belgic
Netherlands. On August 19, 1745, in Glen Finnan, he unfurled his
standard as “James VIII of Scotland and III of England” against
George II and the Hanoverian dynasty of Great Britain. He wore the
Highland costume and won the hearts of the women by his charming
manners and manly beauty.
After a meteoric career, including a brilliant series of marches,
victories, occupation of Holyrood Palace in Edinburgh, invasion of
England almost to London, and sudden retreat, he had to face with
his loyal clansmen the King’s son William, Duke of Cumberland, with
an army specially trained to the use of the bayonet. The two forces
met on Drummossie Moor, near Culloden, April 16, 1746.
Cumberland’s men were in high spirits and fine condition, while the
ill-fed followers of Charles, hungry and weary after a night march,
numbered five thousand. His attempt to surprise the Duke and settle
the issue with cold steel had failed!
Against the advice of his officers, Charles ordered the battle.
After various manœuvres the armies faced each other for the bloody
decision, on which depended the fate of the House of Stuart, the
fortunes of the Highlanders, and the continuance of Scottish
feudalism.
One dreadful surprise awaited the clansmen. Cumberland,
trusting in the bayonet, had carefully drilled each of his men to have
the nerve to neglect the man striking at him with his broadsword, but
to stab at the fellow who, in expectation of dashing aside the bayonet
of the soldier in front of him, would expose his body to the oblique
thrust of his comrade on the right, duly fore-warned.
The day was one of chilly weather, with fitful winds and flurries of
snow. Early in the afternoon, the battle was opened by discharges of
cannon from the side of the rebels. But with this kind of work, the
men from the glens never were satisfied. Indeed, all firearms and
long-range weapons were unpopular with these brave fellows, who,
like Indians and semi-barbarians, enjoyed most that action which
was, as far as possible, independent and personal.
In several of their victories over the royal troops, as at
Prestonpans, for example, they had felt little or no annoyance from
the royal cannon, and had almost lost their fear of artillery.
Cumberland had nine thousand men and eighteen well-served
guns. Here, for the first time, the Highlanders were under heavy fire
of grape and round shot, to which they could not proportionately
reply. It is thought that if Charles at Culloden had let his swordsmen
rush at once upon the enemy the issue might have been different.
For half an hour the Duke’s cannon played effectively upon the
clansmen, who saw scores of their kinsmen stretched upon the
heath. After a few moments’ cannonade from their own side, and still
under the withering fire of the enemy’s heavy guns, the Highlanders
ranged themselves in masses, and according to their clans, made
ready for the terrific onset, which they supposed would decide the
battle. This it did, but not in the way they had hoped. It was the
Mackintoshes, who, unable any longer to brook the unavenged
slaughter of their comrades, broke from the centre of the line and
rushed forward through the smoke and snow to mingle with the
enemy. Yet the order to advance, though never delivered, had
already been given by Charles, the bearer being killed by a cannon
shot.
Cumberland’s troops, seeing the dark masses moving up the
slope, as in a great wave, stood in steady line. As the Highlanders
came to shock, the oblique thrust of the bayonets was a dreadful
surprise, for it prevented hundreds of clansmen from wielding their
favorite weapon, as most of them were thrust through before they
could swing their broadswords, or make the terrible double-handed
sweep with their claymores, on which they had counted. Soon the
moor of Drummossie had proved itself to be the valley of decision for
the hopes of the House of Stuart.
Within two minutes the charge was general along the whole line.
Yet it was as if advancing into semi-darkness of whirling snow and
powder smoke. One survivor of the battle, a Highlander, said that
after rushing forward the first glimpse he received of the Duke’s
troops was, when the cloud of smoke and snow lifted, he saw the
white gaiters of the soldiers. The Duke’s cannon, now loaded with
grapeshot, and the musketry of his solid columns swept the field as
with a hailstorm. The three ranks in the front line of English Hessians
delivered simultaneous volleys, while the regiments of Wolfe—of
whom we Americans have heard in his later career at Quebec—
poured in a flank fire. Nevertheless, the right wing and centre of the
Highlanders fought with even more than usual gallantry and
resolution.
Notwithstanding the fact that they were outflanked, enfiladed,
and met by a heavy musketry fire in front of them, the right wing of
the Highlanders broke Barrel’s regimental front and passed the guns;
but their attack was checked by the bayonets of the second line.
Of the Highlanders who first rushed forward the majority were
hardly able to see their enemy for the smoke, until involved
inextricably among their weapons. Tn their onset, nearly all in the
front ranks fell before either bullets or the piercing weapons used
obliquely, as directed by the Duke, almost every bayonet being bent
or bloody with the strife. Nevertheless, the Highlanders, despite their
impending annihilation, kept on, line after line pushing forward, even
though only a few of those charging last reached the front files of the
royal troops. In parts of the plain, the dead lay three and four deep.
During all this time the Macdonalds, who, because their
ancestors at Bannockburn had fought on the right wing, had ever
afterwards, except on this occasion, occupied this position, would
not fight. They made no onset, and even received the fire of the
English regiments without flinching. They were dissatisfied because
they had been put on the left wing. At last, when the moment of
decision and defeat had come, there being no hope, they also fled
with the other clans.
Charles had yet in reserve his foreign troops, and these, after
the mountaineers had been ruined, he hoped, as he looked on from
the mound at some distance off, would redeem the day. But though
there were instances of bravery among these men, yet, demoralized
by the wreck of the clans coming as fugitives among them, and
seeing the Duke’s army getting ready to charge with the cold steel,
they fled in a body. Thus the rout was complete. Charles, who had
made his last cast for a crown, seemed now unable to realize what
had happened. Confounded, bewildered, and in tears, he seemed
unable to act. His attendants were obliged to turn his horse’s head
and compel him to retreat, Sullivan his friend seizing the horse’s
bridle and dragging him away.
During the uprising of 1745–46, the local clans wore a red or
yellow cross or ribbon, in order to distinguish themselves from the
Stuart Highlanders, who were all dressed in about the same way,
except as to their bonnets. The Jacobites all wore the white cockade,
like that of the Bourbons of France, friends of the Stuarts. One of the
liveliest tunes played by the Highland pipers was “The White
Cockade.” It was the same air, with different words, which the fifers
and drummers of the Continental army played when the flag of the
Revolution was raised in the War of Independence. In fact, in looking
over the American musicians’ repertoire, from 1775 to 1783, one
might almost imagine that the chief music sounded under “the
Congress flag” of thirteen stripes and, after 1777, under “Old Glory”
of later Revolutionary days, was Scottish. Even the strains of
mournful music, over the graves of the slain American patriots, was
“Roslyn Castle.”
One fifth of the Highland army was lost at Culloden. Of the five
regiments which charged the English, almost all the leaders and
front rank men were slain. These numbered nearly a thousand in all.
The actual battle lasted about forty minutes, much of it in distant
firing; but the charge and the crossing of the cold steel were all over
in a quarter of an hour. The number of killed, wounded, and missing
of the royal army was three hundred and ten. The victory was mainly
attributable to the effect of the artillery and musketry of the royalists;
but in Munro’s and Barrel’s regiments, many of the soldiers put to
death one, two, or more Highlanders each, with their bayonets, and
several of the dragoons, sent in pursuit, were known to have cut
down ten or twelve fugitives each in the pursuit.
CHAPTER XVI
THE OLD HIGHLANDS AND THEIR
INHABITANTS